Nuvectis Pharma (NASDAQ:NVCT) Sees Strong Trading Volume Following Insider Buying Activity

Nuvectis Pharma, Inc. (NASDAQ:NVCT) shares saw an uptick in trading volume on Wednesday following insider buying activity. Approximately 141,679 shares traded hands during mid-day trading, an increase of 6% from the previous session’s volume of 134,149 shares.The stock last traded at $19.39 and had previously closed at $18.39.

Specifically, CEO Ron Bentsur purchased 12,500 shares of the stock in a transaction dated Tuesday, June 30th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the chief executive officer directly owned 3,688,424 shares in the company, valued at approximately $73,768,480. This represents a 0.34% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Marlio Charles Mosseri acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the acquisition, the insider directly owned 3,186,576 shares in the company, valued at approximately $58,378,072.32. This trade represents a 1.59% increase in their position. The SEC filing for this purchase provides additional information.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, HC Wainwright increased their price target on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $39.00.

Nuvectis Pharma Stock Performance

The firm has a market capitalization of $519.19 million, a price-to-earnings ratio of -14.94 and a beta of -0.24. The firm has a fifty day moving average price of $12.50 and a 200 day moving average price of $9.83.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Research analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Nuvectis Pharma

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after acquiring an additional 6,084 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Nuvectis Pharma in the 2nd quarter worth approximately $53,000. Bank of America Corp DE increased its stake in Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Nuvectis Pharma by 3,671.4% during the 4th quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock valued at $96,000 after acquiring an additional 12,336 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in Nuvectis Pharma during the second quarter worth approximately $97,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.